These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16121446)

  • 1. Definition of primary mode of action of a combination product. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Aug; 70(164):49848-62. PubMed ID: 16121446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assignment of agency component for review of premarket applications--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58754-8. PubMed ID: 10115697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(246):78158-72. PubMed ID: 12508820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
    Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amendment to examination and investigation sample requirements--FDA. Direct final rule.
    Fed Regist; 1998 Sep; 63(186):51297-9. PubMed ID: 10185810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beverages: bottled water. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Mar; 68(41):9873-82. PubMed ID: 12625359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; partial final rule for combination drug products containing a bronchodilator. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Sep; 66(188):49276-8. PubMed ID: 11758596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.